InventisBio (SH:688382) Xin Lang Cai Jing·2025-11-28 06:52Group 1 - Yifang Biotechnology's stock increased by 5.93%, reaching 29.48 CNY per share, with a trading volume of 388 million CNY and a turnover rate of 3.32%, resulting in a total market capitalization of 17.05 billion CNY [1] - Yifang Biotechnology was established on January 11, 2013, and went public on July 25, 2022. The company is located in the China (Shanghai) Pilot Free Trade Zone and focuses on the research, production, and sales of innovative drugs [1] - The company's main business revenue is entirely derived from technology licensing and cooperation, accounting for 100% of its income [1] Group 2 - According to data, one fund under ICBC Credit Suisse holds a significant position in Yifang Biotechnology, with the Science and Technology Innovation 200 ETF (ICBC) holding 32,800 shares, representing 1.19% of the fund's net value, making it the fourth-largest holding [2] - The Science and Technology Innovation 200 ETF (ICBC) was established on July 23, 2025, with a latest scale of 86.1 million CNY and has achieved a return of 8.47% since inception [2] - The fund manager, He Shun, has been in position for 2 years and 41 days, managing assets totaling 8.558 billion CNY, with the best fund return during his tenure being 56.4% and the worst being 7.83% [2]